Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer

Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer

Osimertinib is first-line treatment for epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC) and has been associated with cardiotoxicity. However, the nature of cardiac remodeling and associated risk factors remains incompletely understood. Retrospective analysis of NSCLC patien...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Jonathan N. Le, Jordan O. Gasho, Olivia Peony, Asneh Singh, Katrina D. Silos, Sungjin Kim, Anthony T. Nguyen, Mitchell Kamrava, Amin Mirhadi, Behrooz Hakimian, Karen L. Reckamp, Kamya Sankar, Raymond H. Mak, Andriana P. Nikolova, Katelyn M. Atkins
Formáid: Alt
Teanga:English
Foilsithe / Cruthaithe: Frontiers Media S.A. 2024-12-01
Sraith:Frontiers in Cardiovascular Medicine
Ábhair:
osimertinib
lung cancer
cardiac toxicity
echocardiogram
EGFR
Rochtain ar líne:https://www.frontiersin.org/articles/10.3389/fcvm.2024.1485033/full

Ar líne

https://www.frontiersin.org/articles/10.3389/fcvm.2024.1485033/full

Míreanna comhchosúla